Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin plus sintilimab for recurrent HER2-expressing endometrial cancer
ChiCTR2500102756Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin and sintilimab in endometrial cancer (EC), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: overall response rate. Started May 2025; status: recruiting.
02
Drugs
disitamab vedotinsintilimab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on ChiCTR2500102756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102756.